Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours.

Nitzsche, B.; Gloesenkamp, C.; Schrader, M.; Ocker, M.; Preissner, R.; Lein, M.; Zakrzewicz, A.; Hoffmann, B.; Höpfner, M.; Höpfner, M

Background: Testicular germ cell tumour (TGCT) is the most common cause of death from solid tumours in young men and especially for platinum-refractory patients novel treatment approaches are urgently needed. Using an in silico screening approach for the detection of novel cancer drugs with inhibitory effects on the tyrosine kinase activity of growth factors (e.g., VEGFR, PDGFR), we identified two compounds (HP-2 and HP-14) with antiangiogenic and antiproliferative potency, which were evaluated in endothelial cell models and TGCT cells.Results: HP-2 and HP-14 effectively inhibited the growth of VEGFR-2-expressing TGCT cell lines (Tera-1, Tera-2 and 2102EP) and endothelial cell models, while they failed to supress the growth of VEGFR-2-lacking tumour cells. cDNA-microarrays revealed an inhibition of the expression of several growth factor receptors and related signal transduction molecules. Vascular endothelial growth factor (VEGF)-induced cell migration was also potently inhibited. Cell cycle-regulating proteins such as p21 and p27 were upregulated, leading to an S-phase arrest. Additional in vivo evaluations confirmed the antiangiogenic potency and good tolerability of the novel substances.Conclusion: Our data show that the identified novel compounds inhibit the growth of TGCT cells and decrease angiogenic microvessel formation. The mode of action involves cell cycle arresting effects and changes in the expression pattern of several angiogenic genes. The novel compounds may qualify as new candidates for targeted treatment of TGCT and merit further evaluation.

GERM cell tumors; TYROSINE; ENDOTHELIAL seeding; PROTEIN-tyrosine kinases; CELL migration; CELL cycle; RESEARCH; NEOVASCULARIZATION inhibitors; PROTEIN kinase inhibitors; RESEARCH methodology; CELL receptors; CELL physiology; MEDICAL cooperation; EVALUATION research; CELL motility; COMPARATIVE studies; TESTIS tumors; TRANSFERASES; GENE expression profiling; CELL lines; PHARMACODYNAMICS

British Journal of Cancer, 2010, Vol 103, Issue 1, p18

0007-0920

Academic Journal

10.1038/sj.bjc.6605725